Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cambendazole is a benzimidazole derivative and small molecule anthelmintic primarily used in veterinary medicine for the treatment of gastrointestinal worm infections in livestock such as horses, cattle, and sheep. It has also been studied for use in humans, particularly for strongyloidiasis. Cambendazole acts by inhibiting glucose uptake and key metabolic enzymes (fumarate reductase and phosphoenolpyruvate carboxykinase) in parasites, leading to energy depletion and paralysis. Additionally, it disrupts microtubule formation by inhibiting tubulin polymerization necessary for cell division in parasites. This results in broad-spectrum activity against nematodes[1][2][3][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cambendazole.